Literature DB >> 24429093

The presence and progression of emphysema in COPD as determined by CT scanning and biomarker expression: a prospective analysis from the ECLIPSE study.

Harvey O Coxson1, Asger Dirksen2, Lisa D Edwards3, Julie C Yates3, Alvar Agusti4, Per Bakke5, Peter Ma Calverley6, Bartolome Celli7, Courtney Crim3, Annelyse Duvoix8, Paola Nasute Fauerbach9, David A Lomas8, William Macnee10, Ruth J Mayer11, Bruce E Miller11, Nestor L Müller9, Stephen I Rennard12, Edwin K Silverman7, Ruth Tal-Singer11, Emiel Fm Wouters13, Jørgen Vestbo14.   

Abstract

BACKGROUND: Emphysema is a key contributor to airflow limitation in chronic obstructive pulmonary disease (COPD) and can be quantified using CT scanning. We investigated the change in CT lung density in a longitudinal, international cohort of patients with COPD. We also explored the potential relation between emphysema and patient characteristics, and investigated if certain circulating biomarkers were associated with decline in CT lung density.
METHODS: We used a random coefficient model to assess predictors of both CT lung density and its longitudinal change over 3 years in 1928 patients with COPD enrolled in the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) study. Lung density was measured for every voxel in the CT scan and after correcting for lung volume was expressed as the density at lowest 15th percentile point of the distribution. This study is registered with ClinicalTrials.gov, number NCT00292552.
FINDINGS: Lung density at baseline was influenced by age, sex, body-mass index, current smoking status and smoking history, and severity of airflow limitation. The observed decline in lung density was variable (mean decline -1·13 g/L [SE 0·06] per year). The annual decline in lung density was more rapid in women (additional -0·41 [SE 0·14] g/L per year, p=0·003) than men and in current smokers (additional -0·29 [SE 0·14] g/L per year, p=0·047) than in former smokers. Circulating levels of the biomarkers surfactant protein D (SP-D) and soluble receptor for advanced glycation endproduct (sRAGE) were significantly associated with both baseline lung density and its decline over time.
INTERPRETATION: This study shows that decline in lung density in COPD can be measured, that it is variable, and related to smoking and gender. We identified potential biochemical predictors of the presence and progression of emphysema. FUNDING: GlaxoSmithKline.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24429093     DOI: 10.1016/S2213-2600(13)70006-7

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN: 2213-2600            Impact factor:   30.700


  100 in total

Review 1.  Biomarkers in airway diseases.

Authors:  Janice M Leung; Don D Sin
Journal:  Can Respir J       Date:  2013 May-Jun       Impact factor: 2.409

Review 2.  Evolving Concepts in Chronic Obstructive Pulmonary Disease Blood-Based Biomarkers.

Authors:  Mario Cazzola; Ermanno Puxeddu; Josuel Ora; Paola Rogliani
Journal:  Mol Diagn Ther       Date:  2019-10       Impact factor: 4.074

3.  Adaptive quantification and longitudinal analysis of pulmonary emphysema with a hidden Markov measure field model.

Authors:  Yrjo Hame; Elsa D Angelini; Eric A Hoffman; R Graham Barr; Andrew F Laine
Journal:  IEEE Trans Med Imaging       Date:  2014-04-15       Impact factor: 10.048

4.  Longitudinal airway remodeling in active and past smokers in a lung cancer screening population.

Authors:  Bertram J Jobst; Oliver Weinheimer; Torben Buschulte; Mila Trauth; Jan Tremper; Stefan Delorme; Nikolaus Becker; Erna Motsch; Marie-Luise Groß; Anke Trotter; Monika Eichinger; Hans-Ulrich Kauczor; Mark O Wielpütz
Journal:  Eur Radiol       Date:  2018-12-14       Impact factor: 5.315

5.  The Challenges of Precision Medicine in COPD.

Authors:  Mario Cazzola; Luigino Calzetta; Paola Rogliani; Maria Gabriella Matera
Journal:  Mol Diagn Ther       Date:  2017-08       Impact factor: 4.074

6.  Lymphatic impairment leads to pulmonary tertiary lymphoid organ formation and alveolar damage.

Authors:  Hasina Outtz Reed; Liqing Wang; Jarrod Sonett; Mei Chen; Jisheng Yang; Larry Li; Petra Aradi; Zoltan Jakus; Jeanine D'Armiento; Wayne W Hancock; Mark L Kahn
Journal:  J Clin Invest       Date:  2019-04-04       Impact factor: 14.808

Review 7.  Advances in Imaging and Automated Quantification of Pulmonary Diseases in Non-neoplastic Diseases.

Authors:  Fernanda Balbinot; Álvaro da Costa Batista Guedes; Douglas Zaione Nascimento; Juliana Fischman Zampieri; Giordano Rafael Tronco Alves; Edson Marchiori; Adalberto Sperb Rubin; Bruno Hochhegger
Journal:  Lung       Date:  2016-09-23       Impact factor: 2.584

8.  Correlation Between Emphysema and Lung Function in Healthy Smokers and Smokers With COPD.

Authors:  Laura H Thomsen; Saher B Shaker; Asger Dirksen; Jesper H Pedersen; Ruth Tal-Singer; Per Bakke; Jørgen Vestbo
Journal:  Chronic Obstr Pulm Dis       Date:  2015-05-19

9.  Texture-based Quantification of Centrilobular Emphysema and Centrilobular Nodularity in Longitudinal CT Scans of Current and Former Smokers.

Authors:  Shoshana B Ginsburg; Jason Zhao; Stephen Humphries; Sungshick Jou; Kunihiro Yagihashi; David A Lynch; Joyce D Schroeder
Journal:  Acad Radiol       Date:  2016-08-27       Impact factor: 3.173

10.  Lung Mass in Smokers.

Authors:  George R Washko; Gregory L Kinney; James C Ross; Raúl San José Estépar; MeiLan K Han; Mark T Dransfield; Victor Kim; Hiroto Hatabu; Carolyn E Come; Russell P Bowler; Edwin K Silverman; James Crapo; David A Lynch; John Hokanson; Alejandro A Diaz
Journal:  Acad Radiol       Date:  2016-12-08       Impact factor: 3.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.